Selenium-Curcumin-PEG Nanoparticles Radiosensitization for Intensity-Modulated Radiation Therapy of Lung Tumor Cells: In Vitro Synergistic Combination Therapy
نویسندگان
1 Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Medical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3 Physics Unit, Department of Radio-oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
4 Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
5 Department of Radiology, School of Paramedical Science, Shiraz University of Medical Sciences, Shiraz, Iran
6 Department of Medical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
7 Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
8 Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
9 Department of Medical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
10 Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
doi
10.31661/jbpe.v0i0.2502-1887چکیده
Background: Lung cancer is a leading cause of cancer-related mortality worldwide, underscoring the need for the development of more effective treatment strategies. Radiotherapy (RT), particularly intensity-modulated radiation therapy (IMRT), has enhanced tumor targeting while minimizing damage to healthy tissues. Nevertheless, radioresistance and challenges posed by the tumor microenvironment limit its efficacy.Objective: Selenium-curcumin-polyethylene glycol 600 nanoparticles (Se-Cur-PEG NPs) analyzed as radiosensitizers in IMRT for lung cancer treatment.Material and Methods: In this experimental study, Se-Cur-PEG NPs were synthesized and characterized for their potential as radiosensitizers.Results: The in vitro toxicity of Se-Cur-PEG NPs against A549 lung cancer cells was evaluated using MTT assays, demonstrating a dose-dependent reduction in cell viability. The combination of Se-Cur-PEG NPs (50 µg mL-1) with IMRT (4 Gy) resulted in a significant enhancement in cell death compared to either treatment alone, indicating a strong synergistic effect (CI=1.21) and a notable sensitizer enhancement ratio (SER=2.5). Intracellular ROS generation analysis confirmed that Se-Cur-PEG NPs amplified IMRT-induced oxidative stress, contributing to increased cancer cell toxicity. Conclusion: These findings suggest that Se-Cur-PEG NPs hold promise as effective radiosensitizers, potentially improving lung cancer RT outcomes.
